Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. SELLAS is a late-stage clinical biopharmaceutical company focused on novel cancer therapeutics, including its lead WT1-targeted immunotherapy GPS and its highly selective CDK9 inhibitor SLS009, and its filings offer structured insight into these programs and the company’s corporate activities.
Here, users can review current and historical Form 10-K and 10-Q reports for detailed information on SELLAS’ business, risk factors, financial condition, and research and development expenses. Form 8-K filings document material events such as quarterly financial results, warrant inducement agreements, sublease amendments for office space in New York, and outcomes of annual stockholder meetings, including director elections and advisory votes on executive compensation.
Investors interested in SELLAS’ capital structure and financing strategy can examine filings that describe warrant exercise transactions, new warrant issuances, and related registration statements on Form S-3. These documents outline the number of shares underlying various warrants, exercise prices, proceeds to the company, and any associated restrictions on future equity offerings or variable rate transactions.
Stock Titan enhances this raw filing data with AI-powered summaries that explain the key points of lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and registration statements are reflected promptly. Users can also monitor governance-related items, such as annual meeting vote results reported on Form 8-K, to track how stockholders are responding to proposals and compensation practices.
For those analyzing SLS as an investment or tracking its oncology pipeline, this page serves as a central hub to review the official regulatory record, with AI-generated highlights that make complex financial and legal language more accessible.
SELLAS LIFE SCIENCES GROUP INC ownership update: BlackRock, Inc. reports beneficial ownership of 12,136,331 shares, representing 6.8% of common stock. The filing attributes sole voting power for 11,966,938 shares and sole dispositive power for 12,136,331 shares, reported by a Managing Director.
SELLAS Life Sciences Group, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 16, 2026 at 8:30 a.m. Eastern Time. The meeting will be held online only via live webcast at www.virtualshareholdermeeting.com/SLS2026.
Stockholders will vote on five proposals, including electing two Class I directors to terms ending in 2029, ratifying Baker Tilly US, LLP as independent registered public accounting firm for 2026, and approving an amendment to the 2023 Equity Plan to increase shares authorized for issuance by 20,000,000. They will also cast a non-binding advisory vote on executive compensation and consider approval of any adjournment or postponement of the meeting if needed to secure enough proxies or establish a quorum.
Holders of SELLAS common stock at the close of business on April 21, 2026, when 184,532,574 shares were outstanding, are entitled to one vote per share. The board recommends voting “FOR” all five proposals and outlines detailed governance practices, committee structures, ownership guidelines, and 2025 executive pay, including total 2025 compensation of $1,877,810 for the Chief Executive Officer.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting zero beneficial ownership of SELLAS Life Sciences Group Inc common stock. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries. The holdings disclosed are in the form of warrants. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/27/2026.
SELLAS Life Sciences Group, Inc. filed and amended a Form S-3 shelf registration to permit the offering, issuance and sale from time to time of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. The registration includes a sales agreement prospectus supplement allowing sales of common stock of up to $150,000,000 under an at-the-market arrangement with TD Securities (USA) LLC (TD Cowen). The base prospectus emphasizes that offerings will occur "from time to time after the effective date" and that specific terms will be set in prospectus supplements. The filing discloses cash and cash equivalents of $71.8 million as of December 31, 2025 and notes subsequent receipt of approximately $42.6 million from the exercise of common stock warrants.
SELLAS Life Sciences Group, Inc. reported a narrower 2025 net loss and a much stronger cash position while advancing its late-stage oncology pipeline. Net loss for 2025 was $26.9 million, or $0.25 per share, compared with $30.9 million, or $0.50 per share, in 2024. Research and development expenses fell to $16.0 million from $19.1 million, mainly after completing enrollment in the Phase 3 REGAL trial of GPS in acute myeloid leukemia. As of December 31, 2025, cash and cash equivalents were $71.8 million, boosted by $67.2 million of 2025 warrant exercise proceeds, with an additional $42.6 million raised from warrant exercises in Q1 2026.
The company is approaching final analysis of the event-driven Phase 3 REGAL study after recording 72 of the required 80 overall-survival events and highlighted positive Phase 2 SLS009 data in relapsed/refractory AML, where overall response was 46% among 35 evaluable patients and median overall survival reached 8.9 months in the least pretreated cohort. SELLAS has begun an 80-patient trial of SLS009 in newly diagnosed AML and entered a European collaboration with IMPACT-AML to study SLS009 with AZA/VEN in about 40 newly diagnosed patients starting in Q2 2026.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company developing novel cancer therapies, led by its WT1-targeting immunotherapy galinpepimut‑S (GPS) and CDK9 inhibitor SLS009 (tambiciclib). The company remains development‑stage, with no product revenue and a history of substantial losses, and expects increasing losses as it advances its pipeline.
GPS is in a registrational Phase 3 REGAL trial as maintenance therapy for acute myeloid leukemia (AML) patients in second complete remission who are not candidates for stem‑cell transplant, with interim analysis completed and the final overall survival readout event‑driven. GPS has shown encouraging earlier‑stage signals in AML, mesothelioma and multiple myeloma and holds multiple FDA and EMA orphan and fast track designations, including Rare Pediatric Disease status in pediatric AML.
SLS009 has shown promising Phase 1 and Phase 2a results in relapsed/refractory AML and lymphomas, including activity in venetoclax‑resistant disease and defined recommended Phase 2 doses. A randomized Phase 2 trial in newly diagnosed AML patients eligible for azacitidine/venetoclax is enrolling, and European access is being expanded via the IMPACT‑AML network. The business depends heavily on successful clinical outcomes, additional financing, third‑party manufacturing and trials, and protection and execution of key licenses with MSK, GenFleet and 3D Medicines.
SELLAS Life Sciences Group, Inc. reports it has received approximately $42.6 million in cash proceeds from the exercise of common stock warrants subsequent to December 31, 2025. This total includes about $26.5 million received by January 8, 2026 and an additional $16.1 million received after that date.
As of March 11, 2026, the company had 179,536,724 shares of common stock outstanding. The update highlights recent warrant exercises that brought in cash and increased the number of shares held by investors exercising those warrants.
SELLAS Life Sciences Group, Inc. received an updated ownership disclosure showing that a group of Anson-affiliated entities and individuals collectively report beneficial ownership of 7,481,178 shares of Common Stock, equal to 4.9% of the class as of the event date.
The stake includes Common Stock underlying outstanding warrants, which are subject to beneficial ownership limits that generally prevent the reporting persons from exceeding 4.99% of the company’s outstanding Common Stock through warrant exercises. The percentage is based on 142,442,239 shares issued and outstanding plus 7,481,178 shares issuable upon warrant exercise.
SELLAS Life Sciences Group, Inc. received an updated institutional ownership report from Highbridge Capital Management, LLC. Highbridge, as investment adviser to certain funds, reports beneficial ownership of 6,514,658 shares of common stock issuable upon exercise of warrants, representing 3.7% of the common stock.
This percentage is calculated using 170,282,026 shares of common stock outstanding as of January 7, 2026. The filing notes that as of December 31, 2025, Highbridge may have been deemed to beneficially own 9,014,658 warrant shares, or 6.0%, based on 142,442,239 shares then outstanding. Highbridge certifies the holdings are in the ordinary course of business and not for influencing control.